Organic growth in revenues and adjusted EBITDA reconcile to reported growth as follows:
Adjusted
Revenue EBITDA
-------------------------------------------------------------------------
Reported growth (4%) (8%)
Impact of currency fluctuations on growth - (8%)
-------------------------------------------------------------------------
Organic growth (4%) -
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Operating income was $19 million compared to $21 million last year in the same period and adjusted EBITDA was $23 million compared to $25 million for the third quarter of 2006. Both were $2 million lower due to the contract cancellation referred to above. There were no adjusting items in the third quarter of either year, and depreciation and amortization was level, year-over-year.
Capital expenditures in the isotopes segment for the quarter were $3
million, compared to none last year. Spending in the quarter related
primarily to the previously announced plans to invest $6 million to expand
our Belgian production facility to meet the growing demand for
Glucotrace(R), a medical imaging agent used extensively in positron
emission tomography (PET)
'/>"/>
| SOURCE MDS Inc. Copyright©2007 PR Newswire. All rights reserved |